ArticleMolecular therapy. Nucleic acids2017
Light-Triggerable Liposomes for Enhanced Endolysosomal Escape and Gene Silencing in PC12 Cells.
Article in Molecular therapy. Nucleic acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 51 citations in OpenAlex.
- Overcoming lysosomal barrier via V-ATPase: an exosome-based co-delivery platform for combined chemo/RNAi therapy against breast cancer.Journal of nanobiotechnology · 2026Article
- Light-triggered nanocarriers for nucleic acid delivery.Drug delivery · 2025Review
- In Vitro Photoselective Gene Transfection of Hepatocellular Carcinoma Cells with Hypericin Lipopolyplexes.ACS applied materials & interfaces · 2024Article
- A Snapshot of Photoresponsive Liposomes in Cancer Chemotherapy and Immunotherapy: Opportunities and Challenges.ACS omega · 2023Review
- Tarin-Loaded Nanoliposomes Activate Apoptosis and Autophagy and Inhibit the Migration of Human Mammary Adenocarcinoma Cells.International journal of nanomedicine · 2023Article
- Non-coding RNAs: Role in diabetic foot and wound healing.World journal of diabetes · 2022Review
- Spotlight on Photoactivatable Liposomes beyond Drug Delivery: An Enabler of Multitargeting of Molecular Pathways.Bioconjugate chemistry · 2022Review
- Physically stimulus-responsive nanoparticles for therapy and diagnosis.Frontiers in chemistry · 2022Review
- Lipid-based nanoparticles for photosensitive drug delivery systems.Journal of pharmaceutical investigation · 2022Review
- Multi-Functional Liposome: A Powerful Theranostic Nano-Platform Enhancing Photodynamic Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Recent advances in liposome formulations for breast cancer therapeutics.Cellular and molecular life sciences : CMLS · 2021Review
- Intracellular Routing and Recognition of Lipid-Based mRNA Nanoparticles.Pharmaceutics · 2021Review
- Review of in vivo optical molecular imaging and sensing from x-ray excitation.Journal of biomedical optics · 2021Review
- Rapid stimulation of cellular Pi uptake by the inositol pyrophosphate InsPChemical science · 2020Article
- Metabolism and Functions of Inositol Pyrophosphates: Insights Gained from the Application of Synthetic Analogues.Molecules (Basel, Switzerland) · 2020Review
- X-ray induced photodynamic therapy (PDT) with a mitochondria-targeted liposome delivery system.Journal of nanobiotechnology · 2020Article
- Article
- Liposome Drug Delivery System across Endothelial Plasma Membrane: Role of Distance between Endothelial Cells and Blood Flow Rate.Molecules (Basel, Switzerland) · 2020Review
- Codelivery of a cytotoxin and photosensitiser via a liposomal nanocarrier: a novel strategy for light-triggered cytosolic release.Nanoscale · 2018Article
- Aromatic Thioacetal-Bridged ROS-Responsive Nanoparticles as Novel Gene Delivery Vehicles.Molecules (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liposomes are an effective gene and/or drug delivery system, widely used in biomedical applications including gene therapy and chemotherapy. Here, we designed a photo-responsive liposome (lipVP) loaded with a photosensitizer verteporfin (VP). This photosensitizer is clinically approved for photodynamic therapy (PDT). LipVP was employed as a DNA carrier for pituitary adenylyl cyclase-activating polypeptide (PACAP) receptor 1 (PAC1R) gene knockdown in PC12 cells. This has been done by incorporating PAC1R antisense oligonucleotides inside the lipVP cavity. Cells that have taken up the lipVP were exposed to light from a UV light source. As a result of this exposure, reactive oxygen species (ROS) were generated from VP, destabilizing the endolysosomal membranes and enhancing the liposomal release of antisense DNA into the cytoplasm. Endolysosomal escape of DNA was documented at different time points based on quantitative analysis of colocalization between fluorescently labeled DNA and endosomes and lysosomes. The released antisense oligonucleotides were found to silence PAC1R mRNA. The efficiency of this photo-induced gene silencing was demonstrated by a 74% ± 5% decrease in PAC1R fluorescence intensity. Following the light-induced DNA transfer into cells, cell differentiation with exposure to two kinds of PACAP peptides was observed to determine the cell phenotypic change after PAC1R gene knockdown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.